The main end point of the edition junior experiment of tenofoy long acting insulin toujeo gla-300 wa

News

TEL：+86-21-33585366（DDT）
     34666753、33588661
FAX：+86-21-34979012
Q Q：  2762556331（Domestic）
      3501899018（Export）
E-mail：info@shyrchem.com
Domestic：sales@shyrchem.com
Export：sales02@shyrchem.com

Your current location：Home > News > Industry News

The main end point of the edition junior experiment of tenofoy long acting insulin toujeo gla-300 wa

Time：2019-11-26 13:37:27 Source： Author：

Today, Sanofi announced that its long-acting insulin toujeo gla-300 (insulin glargine 300 units / ml) reached the primary end point of non inferiority compared with toujeo gla-100 (insulin glargine 100 units / ml) in the edition junior experiment for children and adolescents (6-17 years old) with type 1 diabetes.

About toujeo gla-300

Toujeo gla-300 is a long-acting insulin with insulin content three times that of standard 1ml insulin (100 units / ml). It was approved by FDA in 2015.

Including insulin glargine, the main activity of insulin is to regulate glucose metabolism, through stimulating peripheral glucose uptake, especially the uptake of glucose by skeletal muscle and fat, and through inhibiting the production of liver glucose to achieve the effect of lowering blood glucose.

The edition junior trial , which tested the effectiveness of toujeo gla-300 in reducing HbA1c levels and managing blood glucose fluctuations (incidence of ketosis and hypoglycemia) compared to toujeo gla-100 in type 1 diabetic patients aged between 6 and 17 years with HbA1c levels between 7.5% and 11.0.

The toujeo gla-300 group achieved the primary end point of non inferiority in reducing HbA1c levels, and the incidence of ketosis and severe hypoglycemia (< 54 mg / dl) was relatively lower in the group.

Last Next